Dry Age-Related Macular Degeneration | DecisionBase | 2014

What Do Physicians and U.S. Payers Expect from the First-to-Market Therapies Targeting Geographic Atrophy?

Geographic atrophy (GA) is the advanced dry form of age-related macular degeneration (AMD). Although vision loss caused by GA can be gradual, the disease nonetheless has a steadily increasing negative effect on the lives of affected individuals. No therapies are currently approved for the treatment of GA, and with more than 1.5 million prevalent GA cases across the G7 markets, significant opportunity exists for first-to-market agents.